Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zymeworks, Inc.
Zymeworks’ HER2 Antibody Hits Target In Pivotal Biliary Tract Cancer Trial
The Canadian firm’s bispecific antibody asset improved response rates in advanced biliary tract cancer patients, potentially setting it up to become the first HER2-targeted drug approved for the disease.
Deals In Depth: October 2022
Two $1bn+ alliances were penned in October. Financing reached $7.7bn in biopharma, $636m in device, and $140m in diagnostics.
Zymeworks Deal Expands Jazz’s Potential Oncology Presence
The deal focuses on the HER2-targeting bispecific antibody zanidatamab, in development for multiple solid tumor indications expressing HER2.
GSK Makes ADC Pipeline Comeback With Mersana Deal
The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.
Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Kairos Therapeutics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.